Transcript
Speaker: Okay, hello and welcome to the Trials and Tribulations podcast. I'm Michael Sledge. I'm the Chief Business Officer the Clinical Research Alliance within the School of Medicine at UNC Chapel Hill.
Speaker: And I'm John Buse, the other co-host. I'm a diabetes clinical trialist and a professor of medicine the UNC School of Medicine. I've had the pleasure of working with Rachel Unger for about a decade. She started as a research assistant and has moved herself up to a supervisor and the person that handles most of our pre-award work. So we're going to understand more about career development in clinical trials, but particularly focus on how important pre-award work is.
Speaker: All right, that sounds great. um I have to give our normal disclaimer and remind people that this show is informational. We are not dispensing medical advice, and we would suggest that you speak to your medical providers about that.
Speaker: So, um John, before we get into it with Rachel and have her introduce herself and talk about of sort of her path, Let's spend a moment talking about this term pre-award and what it actually means. So in really plain terms, I think of it as everything between a good idea through the signed agreement to that first patient, first visit.
Speaker: And once you've got first patient, first visit, you're sort of moving out of pre-award. And then lots of pieces to this, right? Feasibility, budget development, effort estimates, coverage analysis, the proposal itself and the protocol, and lots and lots and lots of other paperwork that we're going to get a sense of. summit Does that sound right to you?
Speaker: Yeah. And, you know, from an investigator perspective, it's a black box to me. You know, I i really ah am involved in deciding whether the proposal looks like something that we'd like to do. and And then I'm there at the first patient, first visit, have to do some trainings in between. ah But to me, it's a black box. It's a chasm that has to be...
Speaker: ah ah um crossed. um And in our team, it's Rachel Unger that does that. So what we're going to do here is we're going to talk about how in our research unit, ah five years ago, the process was that each coordinator helped us get through the pre-award process to a first patient, first visit, based on their detailed understanding of the protocol as the person who studies it most along with the site investigator ah to now a process whereby Rachel Unger handles this for our entire group. And this is a large number of protocols she handles
Speaker: every year. And we're also gonna talk about the process by which we got to this process, which really ah is the story of Rachel Unger's professional development.
Speaker: ah So with that, ah Rachel, could you tell us how you came to the clinical research enterprise? If I remember you were an undergraduate ah with a degree in engineering and you just interviewed.
Speaker: Yeah. um So I graduated with a degree in biomedical engineering from North Carolina State University, and I couldn't really find a position out there that met what I was looking for within the biomedical engineering world. Most of what I was interested in is still in research and development area, and I didn't have the education required for that and wasn't really interested in um doing more education at that point in my career. um So actually had a friend who worked in our, or at the UNC Diabetes Care Center and was leaving to go to PA school and approached me with the opportunity and asked if I would be interested in it. And I said, sure. um And that was the beginning of a wonderful journey. um So I started off as a temporary research assistant. Um, and I was working primarily just on one, one research trial that, uh, had 78 patients in it and worked from that study onto working on multiple studies as a research assistant, and then became a permanent research assistant who was also doing a little bit of coordinator work.
Speaker: And then from that point went to be full fledged research coordinator and then, After a period of time of noticing um that there were were a lot of inconsistencies in our unit's work with this pre-award work, ah and discussing with my manager, came up with a kind of um test plan to see if something where everything's centralized would work in terms of putting that pre-award work together.
Speaker: And that is kind of how we got here Yeah. And just tell me a little bit about how you see the difference between a research assistant and a coordinator. Right. So those terms have very different meanings um across the university even. And I talk about that a lot when I'm interviewing people for the research assistant position. In our group, the research assistants complete data entry. They prepare and process laboratory kits.
Speaker: They schedule patients. They um work closely with research monitors to address queries, and basically are doing a lot of supply management, inventory, and administrative work um on top of the laboratory work.
Speaker: Good. And um when you were a coordinator and starting to do your own pre-award work on your own protocols, how did you see that process, you know,
Speaker: an estimate of the number of steps and how proficient you felt at doing that. So balancing the workload of the research coordinator, the primary focus of the workload is participant management. And that involves keeping track of their dose levels and ordering them medication for their study treatment and following up on serious adverse events and all that. Our primary focus is really on the participant's safety and kind of being the middleman between the participant and the site investigator. So to try to balance that with the paperwork in the background can be kind of cumbersome.
Speaker: So I would estimate that my colleagues were probably spending about 20% of their week working on paperwork, whether that was for new studies or for studies that were kind of going on in the background and keeping track of anything that needed to be updated or renewed within their protocols that they were had ongoing. um And there were still significant delays. um So I would estimate that for our group, um the average startup time from the time that we got final approved protocols from a study sponsor after we were selected for a study to the time that we were able to enroll participants was
Speaker: maybe six months if it was a good, a good time. And that could be longer, just depending on what was going on. And i think a lot of that just came to, um i talk about this a lot with all of the ah positions in our group, is that we can kind of get a little bit siloed in our roles and have a little bit of a horse blinder situation going. and it's,
Speaker: difficult with the way that we are assigned to be the primary person for a protocol to really have collaborative work with the other research coordinators. So it was often um coming up in meetings that somebody would be struggling with something in the regulatory world and somebody else would pipe up and be like, oh, I've been dealing with that for three months and I figured out what the issue was.
Speaker: But there's no like and ah prompt to share that kind of new insight. So that is where it felt like my transition role into dealing more with the pre-award work was really important.
Speaker: Yeah. And as an investigator on the outside, what I noticed as we made the transition from every coordinator doing their own pre-award and regulatory work to Rachel Unger doing our pre-award and regulatory work is that things just went much more efficiently with that focus on you know, these are tasks that I can do today and I'll try and get them all done today. If I can't get them done today, I'll get them done tomorrow. Whereas with the coordinator, sometimes with things would fall on the back burner for a week or two because they were so caught up with some of the participant management stuff.
Speaker: John, that sounds like a good segue to move into the sort of process itself. um One note I'll make before we start digging in on that, though, Rachel, is You know, john I've heard John say, i can't remember the number of times, um people seem to find their way to clinical research some kind of way. It's not like they start out with this idea that I'm going to be in clinical research. Same thing happened for me. And what I heard in your story was that exact same thing. You weren't, you know, your biomedical engineering degree wasn't necessarily for you to be in clinical research and yet here you are, right?
Speaker: that is That is definitely a pattern that we've seen. um Okay, so let's talk a little bit about the process itself. Got a few questions to to sort of to lead you through some stuff there. So I'm hearing this pre-award process got centralized, right? So who decided that? Who decided that it was worth doing it in a centralized manner?
Speaker: I would say it was a kind of a group decision, but did ultimately come down to our manager, Alex Cass, kind of pulling the trigger on that. um A lot of my colleagues and people who have actually left clinical research in totality have really not been a fan of the ah regulatory paperwork. They've really, really enjoyed seeing participants and participant management. And the kind of paperwork in the background is really just ground them down to the point of leading the leaving the field. um So we saw that pattern and you know understood that people have strengths and um and that curtailing the workload to people's strengths is the best move for our unit.
Speaker: Well, just a comment. um So you like doing the participant facing work as well. So in a way, this is taking a hit for you doing all the paperwork for everybody. ah But that said, do you get satisfaction recognizing that we've gone from six months startup timelines to I think the shortest one we had was like three weeks on one occasion. um Yeah, it was 26 days.
Speaker: So that's amazing. do Do you get satisfaction from that? Is that going to be able to carry you on for a few years? or Yeah, I do It is rewarding for me to be able to go through the motions and know that I am able to do things in an efficient manner and um that I know the answers and I don't really have to seek them from places unless something wildly has changed in the UNC system. And I think it's a great satisfaction to the other coordinators, to your manager, to the PIs, to the university. Everybody is delighted with this. So um you should feel great about it.
Speaker: Yes, it is wonderful to watch my colleagues be able to put their focus on the participants and know that our research participants are getting, um you know, ah an undistracted coordinator in front of them.
Speaker: Yeah. And this is, Rachel, you're a great example of what we've talked about in prior episodes of like, there's so many people that it takes to make this whole thing work in clinical trials. And so most of us are never, people have never heard of us, don't know what we do. So, but it's critical, you know, if you don't do the things that you do, then the rest of it doesn't happen. So,
Speaker: So you made this transition. imagine there are some things you had to learn. And when you made that transition and then some things that you probably could transfer with you in that. So can you tell us just a little bit about some of those things maybe?
Speaker: Yeah. um So I was already doing, i would say 90% of the work that is involved in the pre-award work that is my role now. um The only couple of things that I kind of took over from other people in our groups would be like the submissions within UNC to create a financials account. But that was really just getting that process started, not dealing with the budget, but uploading it into a portal um to get that Ramsey's account going. um And i took on the full role of doing the feasibility assessments for our group, which was different from what I had been doing previously.
Speaker: And that was and still is um a learning opportunity. ah ah A lot of the feasibility assessments that we receive ask the same questions, but sometimes they ask new ones. And there's, all there are always curve balls that I can't really um find an answer to using ah patient database searches or the ah just institutional knowledge that I have and have to reach out to our providers to kind of get some insight into what they're seeing in clinic that I can't really pull from anywhere else. Um, but still there are new things with the feasibilities all the time. Um, but otherwise i was just, uh, pulling in knowledge and practice from completing different documents and submissions that I had been doing for years prior.
Speaker: Yeah, that's a lot. So um give us some examples. What are some of the other things that you know are the the big important things that you have to do in this pre-award world other than the feasibility part? What what what takes up a lot of time?
Speaker: um I would say the thing that takes up the most time and is kind of the most time sensitive or critical to getting our first patient first patient first visit as soon as possible is IRB submission. So generally with the sort of trials that we do, we um have a reliance agreement with a central ah IRB. And so that still involves submitting to UNC's IRB and going through stipulations there, waiting for conflict of interest um evaluation for our investigators. and then finally getting the language that we need to put into our site consent forms and then having to take that back to get approved by the sponsor. Once that gets approved, then finally submitting to the central IRB. And then once that is all approved, coming back to UNC IRB and getting their final seal of approval. So that process kind of, there's a lot of, um there's a lot of waiting between the steps. And so getting that initiated as soon as possible and then addressing
Speaker: Once the waiting period is over, once one of the waiting periods are over, hopping back in to address whatever questions there are or taking the next step is really important to keeping that flow going constantly. um And then kind of in the background when, well, in between um other internal submissions, and like getting our investigational drug services submissions in with the healthcare side and and We also have to work on Epic builds for the actual protocols that we are working with.
Speaker: So we have the calendars that we have from our protocol and the pharmacy builds. So those things are all happening kind of in the background while waiting for all the other pieces to fall into place as well.
Speaker: And then the kind of more regulatory paperwork that is more overarching with um FDA 1572s and delegation logs and training and documentation of training um and getting financial disclosure forms and all that jazz.
Speaker: That's a lot, John. Let me let me add a couple of comments before you go. One, just for our listeners, Rachel, throughout this term, EPIC, that is the the electronic health record platform that UNC Health and really a lot of the country's health systems use. So just want to make sure people understood that.
Speaker: John? Yeah. And just to put a finer point on it, you've mentioned half a dozen, maybe 10 things that you do, some of them multi-step like the IRB. But I saw a list the other day.
Speaker: It must have been 60 things. um Did you actually count them up? How many things are on your list for a protocol? ah Yeah, well, including my work as a supervisor of all of our research assistants, it it was 89 tasks that I have. And and to put a, ah this you know, a those 89 tasks, because you do it over and over and over again, you've gotten to be very good at it.
Speaker: um um And so the the sort of improvement from six months to first patient first visit on a good day a few years ago to now probably two months um ah might be a ah good day for us now.
Speaker: ah How much of it do you think is just being on top of the task or because of the experience you developed, the sort of greater accuracy in performing the task, namely that you do it right so it doesn't come back from the IRB saying, ah, you know, you didn't do this.
Speaker: I think that's 100% it. um So I am able to submit things and anticipate any questions that might come up from the IRB and kind of address those ahead of time. If there are things that we're still waiting on, I can let them know ahead of time that you don't need to come back and ask me for this because I know I don't have it. um Or that I don't have to ask the question to anyone else on my team. I don't have to send a message out to anyone and wait for them to respond. I'm just able to complete whatever I'm working on in real time. And I think that both of those things really save a lot of time and help us move more efficiently.
Speaker: Can ask one other follow-up question, Michael? Because it this didn't occur to me until just now. Do you think if we had a stable of Rachel Unger's, 10 or 20 of them, could a central office take over this for all the clinical protocols at UNC?
Speaker: Or do you sort of need that individual unit experience and the individual relationships with the coordinators and the investigators to do that? um so that's a great question. i have never thought of that possibility. So, I'm not a hundred percent sure but there are a lot of components that are very easily transferable ah between studies. So I do think that there could be some level of, um, centralization and yeah, that's a really good question. I think some, some components of it are just down to,
Speaker: nitty-gritty of what each staff member's delegatable tasks are or what kind of the vision for their role is. But that is an interesting question. It may be horrifying to you, actually. I'll tell you, I've had a lot of experience over my career with centralizing things, right?
Speaker: and And what comes up for me, I think it is an awesome question. And what comes up for me is that, yes, it's possible, but I think the balance is if you lose that the kind of stuff you were pointing to, John, of the the sort of... vibe and the relationships with the coordinators and the PIs and all that stuff that's on the ground right there at the site, if you lose that, that's going to be disastrous. So however you do the organization of it, like you got my opinion is you've got to have that strong link back to the sites. If you lose that, you're done.
Speaker: All right, so let me clarify something, and then we're going to move on to the next segment with John. Those 89 steps, Rachel, that's 89 steps for every protocol, right?
Speaker: Um, yes. And that's including, so I do for our group, I also keep up with but the post award kind of regulatory, um, matters as well. So anytime there's a new protocol that comes through when we're in the middle of a study, I train every, all of our staff on that. Um, anytime a new staff member comes on board, I'm onboarding them and all components really. Um, so that, um,
Speaker: a lot of, there are a lot of different faces that I put on for our group. So that plays into that. But Michael, I think what you were getting at is how many protocols do you think we do in a in a year? How many feasibility assessments and then how many actually go to that first patient first visit?
Speaker: um Yes. So I would say that i complete probably 20 to 30 feasibilities a year. And then we have kind of a constant you know, the plus or minus, we have 20 to 25 trials ongoing at a time. So probably i would say an influx of five to 10 trials per year and with some of those trickling, some of the older ones trickling out throughout the year as well. Most valuable employee. That's all I got to say.
Speaker: Yeah. I mean, and just multi multiply this across the portfolio that UNC has, for example, and you want to grow that portfolio. And what's really sticking for me right now is this whole thing about 89 steps.
Speaker: You better have somebody trained and trained and trained, right? And the value you lose when you lose that person that knows those 89 steps, man, what what a cost to try to replace that person. That's a big burden in your system. So um hats off to you, Rachel. I do think when you were talking about those 89 steps, um That old song, 100 bottles of beer on the wall came to mind for me. So John, maybe we need to think about a change in the title for this episode. It's not 89 bottles of beer on the wall. It is a lot.
Speaker: So, you know, one other thing we talked a little bit about, you know, whether this could be, this model could be centralized for the entire university. Our clinical trial unit is probably,
Speaker: 3% of the university's clinical trials, maybe be less than that. So it would have to be a big group. um What things are you looking forward to next? what What else could you do to make this process more efficient for the the site investigators, for the coordinators, for yourself?
Speaker: So I am actually getting ready to start a process of um training up a research assistant to help me out with some of the more administrative components of my work um of tracking down investigators to get them to sign something or preparing docu signs or other kind of um simpler tasks that would not um need to have as much of the like experience or greater knowledge of what's really going on to complete, but that would take some of those 89 tasks off of my list so that I can focus more on the um the ones that do require some more institutional knowledge and experience.
Speaker: So we'll see how it goes. And har horrifying as it might be, you know, one day, you know, you're going to want to spread your wings even wider and perhaps manage a clinical trials unit or, you know, work for a big CRO or pharma or one of those things. And I think having a a protege that you bring in ah to start their professional development is a really good thing for our unit as well.
Speaker: Anything's either at the university level or if you're going to give advice to CROs or sponsors, anything that you see is just a ridiculous waste of time that we could do better?
Speaker: i don i think that the most important thing is really just... communication at all levels and just um really emphasize that it's important to keep all of in interested parties copied on emails and in in the know of what's going on. It happens a lot on both sides that um we may have had a discussion with someone already within a group, but then once, you know, a couple weeks later, we're kind of starting from ground zero with that. So just
Speaker: It saves a lot of time when there's good communication between all groups. All right. So lot of good stuff there. Let's see if we can wrap up this portion and let Rachel get back to step number 73 or whichever one she's on right now.
Speaker: um One thing I would point out, you know, the the CRA is not on the site side, it's on the coordinating center side of that. And John, I know this this would resonate with you. But if you think about, like, I've been involved in global trials, literally 60 countries, 30,000, 40,000 patients. I don't remember how many sites.
Speaker: Think about all those steps multiplied by a trial that big and think about the level of effort it takes to get through a study. It's mind boggling when you stop and think about it from that perspective.
Speaker: Rachel, what else or you do you need to tell us today? Your coordinator friends, your pre-award friends are all listening out there. They're waiting for you to wrap this up and give them some great advice. What would you tell them?
Speaker: I would just say that the the people around you are your biggest resource and that if you're struggling with something, probably somebody else has too. And to just reach out to those around you for help. And if you have the capability to orient your unit so that you have somebody who's handling everything, that's great. But as you mentioned earlier,
Speaker: it is kind of a little bit of a, um, a risk. If you do lose that person who is handling all of this work, then your coordinators who haven't been doing this work there on their own are kind of left to pick up the pieces, um, or can be, and may not really have the experience or familiarity. So it is something to consider. Um, but I do think that we have, you know, more than cut our startup time in half and, um,
Speaker: have really just streamlined every part of our startup process with this kind of change in role. JOHN MCWHORTERSENGIEWICZ- That's great Let's hope some ah HR people from around the world are listening to today's episode so they can help um they can understand like the value of people and the kind of roles that you do and make sure that we stay competitive and keep great people like you in here.
Speaker: John, you want to recap this episode? Yeah. So the pre-award work is really, really important and it can be done efficiently, getting you to a first patient first visit in two months instead of six months.
Speaker: And that's really important in these competitive enrollment trials where an additional four months of recruiting can make the difference between meeting your targets and your budget and failing, uh, completely.
Speaker: Um, and so I am personally grateful for, uh, ah Rachel Unger's service to to our unit. Yeah, Rachel, thank you so much for joining us today. It's been a pleasure to have you and really to gain some insight from the type of work that you're doing in this space.
Speaker: Okay, that's episode four, except for we got some segments coming up here that we'll get to actually right now.
Speaker: Okay, so now we're gonna move into, we have a segment or two that we try to do every time after we've gotten through the main idea of the show.
Speaker: And today we're gonna do one called Myth Versus Fact. So I'm gonna read the myth and Rachel, you're in the hot seat. You get the call myth or fact on this, okay?
Speaker: So myth or fact, pre-award is paperwork. It is the administrative step you get through before the real work starts. I would say myth. um The pre-award work is a lot does involve a lot of paperwork, but it really gives you an idea of what to expect with the trial and really familiarizing yourself with the protocol and the effort that is going to be required from the study.
Speaker: And if you don't do it well or don't do it right, it can kill the trial and it can negatively impact your relationship with study sponsors so that maybe you aren't selected for the next trial that comes through. Whereas if it is really efficient and works well, then you may be at the top of the list for the next break breakthrough trial that comes around the corner.
Speaker: Those are really great points. Okay. Thanks again. That's a wrap for episode four.
Speaker: Episode five coming up is we're going to have one of our old friends from campus that worked with John particular for long time. Laura Vieira is going to join us and we're going to talk about the CRC story, the clinical research coordinator story.
Speaker: So we're looking forward to that. I want to thank listeners. I want to invite you to share this with researchers, coordinators, sponsors, partners, really anybody that's in the community that has an interest in clinical research.
Speaker: John, any last words from you? No, this has been a delight. it's ah Rachel's story is a great story, and the work that she does is so high impact.
Speaker: I do think this episode is going to be helpful to many people. All right, folks, see you next time.

